PREPARE-iVAC Trial

NCT ID: NCT05924685

Last Updated: 2024-03-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-22
• Study Completion Date: 2024-02-27

Brief Summary

Objective: To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior immunogenicity of COVID-19 vaccination as measured by neutralizing antibody titer against the Omicron XBB.1.5 strain.

Trial design: Multicentre, open-label randomized controlled clinical trial, for a duration of at least 10 weeks with an optional extension to 18 weeks.

Trial population: Kidney transplant recipients, 18 years or older, who are at least 6 months after transplantation, with a functioning kidney transplant, using MMF/MPA in combination with at least one other immunosuppressant including a calcineurin inhibitor (CNI), with at least 3 previous COVID-19 vaccinations (=basic COVID-19 immunisation).

Interventions:

Patients will be randomized into one of two equally sized groups, with either continuation of their current immunosuppressive regimen including MMF/MPA or replacement of MMF/MPA by everolimus during at least six weeks before until four weeks after the last vaccination. Patients will receive a repeated COVID-19 vaccination with the monovalent Omicron XBB.1.5 vaccine, 28 days thereafter they can opt to also receive two herpes zoster vaccinations with the Recombinant Zoster Vaccine (RZV) with an interval between the first and second dose of 28 days.

Main trial endpoints:

The neutralizing antibody titer against the Omicron XBB.1.5. strain 28 days after monovalent Omicron XBB.1.5 COVID-19 vaccination in patients continuing MMF/MPA compared to patients who switched to everolimus.

Secondary trial endpoints:

• SARS-CoV-2 specific anti-S1 antibody level at 28 and 56 days after COVID-19 vaccination
• Varicella zoster specific anti-gE antibody level 28 days after 1st and 2nd herpes zoster vaccination
• SARS-CoV-2 specific T-cell response 28 days after COVID-19 vaccination
• Varicella zoster specific T-cell response 28 days after 2nd herpes zoster vaccination
• Safety in terms of incidence of acute rejection, kidney function decline, SAEs, AESIs and solicited local and systemic AEs after COVID-19 and herpes zoster vaccination

Detailed Description

Rationale: The immunogenicity after vaccination against SARS-CoV-2 and other pathogens is diminished in kidney transplant recipients. This patient group therefore remains extremely vulnerable for viral infections despite vaccination. This impaired immune response is related to the use of immunosuppressive agents, especially Mycophenolate Mofetil/Mycophenolic Acid (MMF/MPA). Patients that use everolimus instead of MMF/MPA elicit a higher immune response after vaccination.

Objective

Primary objective:

To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior immunogenicity of COVID-19 vaccination as measured by neutralizing antibody titer against the Omicron XBB.1.5 strain.

Secondary objectives:

• To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior humoral immunogenicity of

• COVID-19 vaccination as measured by SARS-CoV-2 specific anti-S1 antibody levels
• herpes zoster vaccination as measured by varicella zoster specific anti-gE antibody levels
• To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior cellular immunogenicity of

• COVID-19 vaccination as measured by SARS-CoV-2 specific T-cell response
• herpes zoster vaccination as measured by varicella zoster specific T-cell response
• To evaluate safety of replacement of MMF/MPA by everolimus in terms of

• incidence of treated acute rejection, kidney function decline, incidence of serious adverse events (SAEs)
• incidence of adverse events of special interest (AESI) of immunosuppression
• incidence of solicited adverse events (AEs) of COVID-19 vaccination
• incidence of solicited AEs of herpes zoster vaccination

This is a multicentre, open-label, controlled, randomized study to evaluate replacement of MMF/MPA by everolimus in KTR on immunogenicity and safety after vaccination.

The seven participating study sites are Amsterdam UMC, Erasmus MC, Leiden UMC, Maastricht UMC+, Radboudumc, UMC Groningen and UMC Utrecht.

At the first study visit, eligibility for study participation will be checked, blood will be drawn, and participants will subsequently be 1:1 randomised to:

1. Continue immunosuppressive therapy with MMF/MPA

2. Replace immunosuppressive therapy with MMF/MPA by everolimus

After randomisation, the study will continue in 2 parts:

Part 1 - Run-in and COVID-19 vaccination (≥6 weeks + 28 days) The aim of this phase is to first ensure complete washout of MMF/MPA and attaining optimal trough levels of everolimus in patients randomized to everolimus.

To monitor tolerability, safety and trough levels, participants will be invited at week 1 and week 3 after randomisation for a blood withdrawal and spot urine collection.

At least 6 weeks after randomisation, patients will receive the COVID-19 vaccination (=baseline visit). After 28 days patients will be invited for a study visit for blood withdrawal.

Part 2 (optional) - Herpes zoster vaccination (+56 days) Patients that opted to participate in this part of the study will continue their randomised treatment for the next 56 days. During this period patients will receive 2 herpes zoster vaccinations with an interval of 28 days between each vaccination. At 28 days after the second vaccination patients will be invited for the last study visit for blood withdrawal.

After completion of the study (either 28 days after COVID-19 vaccination or 28 days after the last herpes zoster vaccination) patients will be offered the option to continue everolimus instead of MMF/MPA as part of shared clinical decision making.

Conditions

COVID-19 Vaccines; Varicella Zoster Vaccine; Vaccine Response; Immunosuppression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Continue immunosuppressive therapy with MMF/MPA

Kidney transplant recipients with maintenance therapy, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).

Group Type: ACTIVE_COMPARATOR

COVID-19 vaccination

Intervention Type: BIOLOGICAL

Vaccination

Replace immunosuppressive therapy with MMF/MPA by everolimus

Kidney transplant recipients replacing MMF/MPA by everolimus for at least six weeks, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).

Group Type: ACTIVE_COMPARATOR

COVID-19 vaccination

Intervention Type: BIOLOGICAL

Vaccination

Interventions

COVID-19 vaccination

Vaccination

Intervention Type: BIOLOGICAL

Other Intervention Names

the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccination

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• ≥6 months after kidney transplantation
• Maintenance immunosuppressive therapy consisting of either triple or dual therapy including MMF/MPA with a minimum daily dose of 1000 mg (MMF) or 720 mg (MPA) and a CNI
• Eligible for the vaccinations as described by the instructions of the manufacturers of the vaccines (e.g. received 3 previous COVID-19 vaccinations as part of the primary COVID-19 immunisation)
• Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained)
• Willing to adhere to the protocol and be available during the study period

Exclusion Criteria

• Previous CNI trough levels not sufficient according to the discretion of the treating physician
• More than two previous kidney transplantations
• Calculated level of panel reactive antibodies prior to last transplantation above 85%
• Evidence of DSAs
• Signs of acute rejection during the preceding year
• Multi-organ transplant recipient
• History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s)
• Contra-indications for use of everolimus according to the opinion of the treating physician
• Active COVID-19 disease
• Active malignancy, except non-melanoma skin cancer
• Inherited immune deficiency
• Infection with Human Immunodeficiency Virus (HIV)
• Administration of T-cell, B-cell, or plasma cell depleting antibodies during the last 6 months
• Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
• Subjects with severe systemic infections, current or within the two weeks prior to randomisation
• Subjects with severe restrictive or obstructive pulmonary disorders
• Subjects with severe hypercholesterolemia or hypertriglyceridemia that cannot be controlled
• Subjects with white blood cell (WBC) count ≤ 2,000/mm3 or with platelet count ≤ 50,000/mm3 at last outpatient clinic visit
• Proteinuria > 1 gram/day at last outpatient clinic visit
• Simultaneous participation in another interventional study that will likely influence the study outcomes
• Subject who are actively trying to get pregnant or are pregnant

• Active varicella or herpes zoster disease
• Herpes zoster vaccination with the live attenuated vaccine (Zostavax) or varicella vaccination (Provarivax) during the conduct of the study
• Previous herpes zoster vaccination with the RZV

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

Sponsor Role: collaborator

Radboud University Medical Center

OTHER

Sponsor Role: collaborator

Erasmus Medical Center

OTHER

Sponsor Role: collaborator

UMC Utrecht

OTHER

Sponsor Role: collaborator

Leiden University Medical Center

OTHER

Sponsor Role: collaborator

Maastricht University Medical Center

OTHER

Sponsor Role: collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

Sponsor Role: collaborator

Dutch Kidney Foundation

OTHER

Sponsor Role: collaborator

University Medical Center Groningen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jan-Stephan F Sanders, MD PhD

Role: PRINCIPAL_INVESTIGATOR

University Medical Center Groningen

Locations

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands

Maastricht University Medical Center

Maastricht, Limburg, Netherlands

Amsterdam University Medical Center

Amsterdam, North Holland, Netherlands

Leiden University Medical Center

Leiden, South Holland, Netherlands

Erasmus Medical Center

Rotterdam, South Holland, Netherlands

University Medical Center Groningen

Groningen, , Netherlands

University Medical Center Utrecht

Utrecht, , Netherlands

Countries

Netherlands

Other Identifiers

2023-503894-39-00

Identifier Type: OTHER

Identifier Source: secondary_id

11442

Identifier Type: -

Identifier Source: org_study_id